Metastatic kidney cancer: Choice of first-line therapy
https://doi.org/10.17650/1726-9776-2014-10-3-43-48
Abstract
The current practice in prescribing targeted agents for patients with metastatic kidney cancer (KC) is based on the results of a few large-scale multicenter randomized trials of the efficacy of different drugs in different clinical situations. Most international and national oncology and urology associations recommend 3 standard treatment options: 1) bevaсizumab in combination with interferon; 2) sunitinib; 3) pazopanib as first-line therapy in patients with good and intermediate risk metastatic KC. The valid choice of a drug for first-line therapy is one of the topical problems of real clinical practice. The criteria for choosing a drug are primarily its efficacy and toxicity profile. In addition, the specific features of a patient’s health status, the presence of different intercurrent diseases, lifestyle, and professional peculiarities also affect the choice of a treatment regimen. The paper comparatively reviews the efficacy and toxicity of bevaсizumab in combination with interferon at different doses, those of sunitinib and pazopanib, on the basis of which the choice of a drug for the therapy of patients with good and intermediate risk metastatic KC may be planned in a specific clinical situation.
About the Author
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research Institute; Department of Urology with Course of Urologic Oncology, Peoples’ Friendship University of Russia, Moscow; Department of Oncology, Medical Institute for Postgraduate Training of Physicians, Moscow State University of Food Productions
Russian Federation
Russian Federation
References
1. Ljungberg B., Bensalah K., Bex A. et al. EAU Guidelines on renal cell carcinoma. http://www.uroweb.org/gls/pdf/10%20 Renal%20Cell%20Carcinoma_LR.pdf.
2. National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer, V.2.2012. http://www.nccn.org. Accessed March 5, 2012.
3. Escudier B., Eisen T., Porta C. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2012;23(Suppl 7): vii65-vii71.
4. Motzer R.J., Hutson T., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90.
5. Escudier B., Pluzanska A., Koralewski P. et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103–11.
6. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8.
7. Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722–31.
8. Negrier S., Gwenaelle G., Peroll D. et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12:673–80.
9. Motzer R.J., Barrios C.H., Kim T.M. et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31(suppl);abstr 4504.
10. Melichar B., Bracarda S., Matveev V. et al. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol 2013;24(9):2396–402.
11. Patard J.-J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633–43.
12. Hurwitz H.I., Saltz L.B., Van Cutsem E. et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29(13):1757–64.
13. Melichar B., Koralewski P., Ravaud A. et al. First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19:1470–6.
Review
For citations:
Alekseev B.Ya. Metastatic kidney cancer: Choice of first-line therapy. Cancer Urology. 2014;10(3):43-48. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-3-43-48
Views:
1124
Email this article 